EUVIMEDEUVIMED entdecken
Multizentrische Studie

Type 3 Macular Neovascularization in Age-related Macular Degeneration

Riccardo Sacconi, Paolo Forte, Giulia Corradetti, Eliana Costanzo, Vittorio Capuano, Elodie Bousquet, Federico Beretta, Serena Iannuzzi, Maria Sole Polito, Massimo Nicolò, Mariacristina Parravano, Eric Souied und 4 weitere

Ophthalmology Retina · 2025-06 · 9 (6) · 546-555

DOI: 10.1016/j.oret.2024.11.011 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Ophthalmology Retina, 2025-06. Verfasst von Riccardo Sacconi und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; Division of Head and Neck, Ophthalmology Unit, Istituto di Ricovero e Cura a C…. Hauptthemen laut MEDLINE: Tomography, Optical Coherence, Wet Macular Degeneration, Visual Acuity, Fluorescein Angiography. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To identify baseline OCT predictors of the 3-year macular atrophy (MA) development for type 3 (T3) macular neovascularization (MNV) secondary to neovascular age-related macular degeneration (nAMD) treated by anti-VEGF therapy. DESIGN: Multicenter, retrospective, longitudinal study. PARTICIPANTS: We included patients with treatment-naive T3 MNV secondary to nAMD at baseline, treated with anti-VEGF during a 3-year follow-up. METHODS: Patients were identified from 6 retinal referral institutions: (1) San Raffaele University, Milan, Italy; (2) University of Genova, Genova, Italy; (3) Doheny Eye Institute, Los Angeles; (4) Stein Eye Institute, Los Angeles; (5) University of Paris Est, Creteil, France; and (6) Istituto di Ricovero e Cura a Carattere Scientifico Bietti Foundation, Rome, Italy. Several baseline predictors of 3-year MA area were analyzed based on structural OCT and demographics. MAIN OUTCOME MEASURES: Multivariate analysis to identify baseline independent predictors of the 3-year MA development for T3 MNV secondary to nAMD treated by anti-VEGF therapy. RESULTS: We included 131 eyes of 131 patients (mean age, 80 ± 6 years; 81% females). Best-corrected visual acuity was 0.49 ± 0.40 logarithm of the minimum angle of resolution (logMAR) at the baseline and significantly decreased to 0.59 ± 0.43 logMAR at the end of 3-year follow-up (P < 0.001). Patients were treated with 11 ± 6 anti-VEGF injections and developed atrophy in 75% of cases (from 18% at the baseline). Eyes that developed 3-year MA were treated with a significantly lower number of injections compared with eyes without MA (9.9 ± 5.5 vs. 14.7 ± 7.2 injections, P < 0.001). The most relevant independent predictors at baseline of MA area at 3-year follow-up were: area of MA at baseline (P < 0.001), age-related macular degeneration phenotype (presence of reticular pseudodrusen) (P = 0.017), baseline presence of nascent geographic atrophy (P = 0.008), and the baseline presence of subretinal hyperreflective material (P = 0.002). CONCLUSIONS: Macular atrophy development is a frequent complication of T3 MNV treated with anti-VEGF injections. Several factors could be considered baseline predictors of atrophy development during the anti-VEGF treatment. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tomography, Optical CoherenceWet Macular DegenerationVisual AcuityFluorescein AngiographyMacula LuteaHumansFemaleRetrospective StudiesMaleFollow-Up StudiesIntravitreal InjectionsAngiogenesis InhibitorsAgedVascular Endothelial Growth Factor AFundus OculiAged, 80 and overRanibizumabTime Factors

Stichwörter der Autor:innen

Age-related macular degenerationBiomarkerOCTPredictorType 3 neovascularization

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumab

Autor:innen und Institutionen

  • School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; Division of Head and Neck, Ophthalmology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, Milan…
  • Department of Ophthalmology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino, Eye Unit, Genoa, Italy; Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e…
  • Doheny Eye Institute, University of California, Los Angeles, California; Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California, Los Angeles, California.
  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione Bietti, Rome, Italy.
  • Department of Ophthalmology, Hospital Intercommunal de Creteil, University Paris Est Creteil, Creteil, France.
  • Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California, Los Angeles, California.

Zitieren

APA

Sacconi, R., Forte, P., Corradetti, G., Costanzo, E., Capuano, V., Bousquet, E., Beretta, F., Iannuzzi, S., Polito, M. S., Nicolò, M., Parravano, M., Souied, E., Sarraf, D., Sadda, S., Bandello, F., & Querques, G. (2025). Type 3 Macular Neovascularization in Age-related Macular Degeneration. Ophthalmology Retina, 9(6), 546-555. https://doi.org/10.1016/j.oret.2024.11.011

Vancouver

Sacconi R, Forte P, Corradetti G, Costanzo E, Capuano V, Bousquet E, et al. Type 3 Macular Neovascularization in Age-related Macular Degeneration. Ophthalmology Retina. 2025;9(6):546-555. doi:10.1016/j.oret.2024.11.011

BibTeX
@article{Sacconi2025,
  author = {Sacconi, Riccardo and Forte, Paolo and Corradetti, Giulia and Costanzo, Eliana and Capuano, Vittorio and Bousquet, Elodie and Beretta, Federico and Iannuzzi, Serena and Polito, Maria Sole and Nicolò, Massimo and Parravano, Mariacristina and Souied, Eric and Sarraf, David and Sadda, SriniVas and Bandello, Francesco and Querques, Giuseppe},
  title = {Type 3 Macular Neovascularization in Age-related Macular Degeneration},
  journal = {Ophthalmology Retina},
  year = {2025},
  volume = {9},
  number = {6},
  pages = {546--555},
  doi = {10.1016/j.oret.2024.11.011}
}
Kostenlos starten →